1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material | Telmisartan and Amlodipine Tablets 40 mg/5 mg; 40 mg/10 mg; 80 mg/5 mg and 80 mg/10 mg
Manufacturer | Lupin Limited
             | Goa 403 722
             | INDIA.
Distributor | Lupin Pharmaceuticals, Inc.
             | Harborplace Tower, 21st Floor
             | 111, South Calvert Street
             | Baltimore, MD 21202
             | United States
             | Tel.  001-410-576-2000
             | Fax.  001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients | CAS
Telmisartan | 144701-48-4
Amlodipine | 111470-99-6

3. HAZARDOUS IDENTIFICATION

Fire and Explosion | Assume that this product is capable of sustaining combustion.
Health | Telmisartan and amlodipine tablets are contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan, amlodipine, or any other component of this product.
          | Do not co-administer aliskiren with telmisartan and amlodipine tablets in patients with diabetes
Environment | No information is available about the potential of this product to produce adverse environmental effects.
4. FIRST AID MEASURES

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

OVERDOSAGE

Telmisartan
Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan tablets would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.

Amlodipine
Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional overdosage of amlodipine is limited.

Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m² basis) caused a marked peripheral vasodilation and hypotension.

If massive overdose should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential. Should hypotension occur, provide cardiovascular support including elevation of the extremities and the judicious administration of fluids. If hypotension remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.
5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards
Assume that this product is capable of sustaining combustion.

Extinguishing Media
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures
For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.

Hazardous Combustion Products
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods
Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling
No special precautions are necessary when handling packed product. In case of accident, avoid breathing dust from crushed tablets. Avoid contact with skin and eyes. Wash hands after use.

Storage
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP controlled room temperature].

Do not remove from blisters until immediately before administration. Protect from moisture and light.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
9. PHYSICAL & CHEMICAL PROPERTIES

Physical Form

Telmisartan and amlodipine tablets are available as

40 mg/5 mg
Oval shaped, biconvex, bilayer, uncoated tablets where Amlodipine layer is white but may have yellow specks, debossed with ‘C54’ and Telmisartan layer is yellow in colour but may have white specks, debossed with ‘LU’.

40 mg/10 mg
Oval shaped, biconvex, bilayer, uncoated tablets where Amlodipine layer is white but may have red specks, debossed with ‘C55’ and Telmisartan layer is red in colour but may have white specks, debossed with ‘LU’.

80 mg/5 mg
Capsule shaped, biconvex, bilayer, uncoated tablets where Amlodipine layer is white but may have red specks, debossed with ‘C56’ and Telmisartan layer is red in colour but may have white specks, debossed with ‘LU’.

80 mg/10 mg
Capsule shaped, biconvex, bilayer, uncoated tablet where Amlodipine layer is white but may have yellow specks, debossed with ‘C57’ and Telmisartan layer is yellow in colour but may have white specks, debossed with ‘LU’.

Telmisartan and amlodipine tablets are supplied for oral administration in the following strengths and package configurations:

<table>
<thead>
<tr>
<th>Tablet strength</th>
<th>Package Configuration</th>
<th>NDC#</th>
</tr>
</thead>
<tbody>
<tr>
<td>(telmisartan/amlodipine besylate equivalent to amlodipine) mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 mg/5 mg</td>
<td>Bottles of 30, Bottles of 90, A box containing 100 Tablets (10 X 10 unit-dose)</td>
<td>68180-196-06, 68180-196-09, 68180-196-13</td>
</tr>
<tr>
<td>40 mg/10 mg</td>
<td>Bottles of 30, Bottles of 90, A box containing 100 Tablets (10 X 10 unit-dose)</td>
<td>68180-197-06, 68180-197-09, 68180-197-13</td>
</tr>
<tr>
<td>80 mg/5 mg</td>
<td>Bottles of 30, Bottles of 90, A box containing 100 Tablets (10 X 10 unit-dose)</td>
<td>68180-198-06, 68180-198-09, 68180-198-13</td>
</tr>
<tr>
<td>80 mg/10 mg</td>
<td>Bottles of 30, Bottles of 90, A box containing 100 Tablets (10 X 10 unit-dose)</td>
<td>68180-199-06, 68180-199-09, 68180-199-13</td>
</tr>
</tbody>
</table>
10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis, Mutagenesis, Impairment of Fertility

**Telmisartan**

There was no evidence of carcinogenicity when telmisartan was administered in the diet to mice and rats for up to 2 years. The highest doses administered to mice (1000 mg/kg/day) and rats (100 mg/kg/day) are, on a mg/m² basis, about 59 and 13 times, respectively, the maximum recommended human dose (MRHD) of telmisartan. These same doses have been shown to provide average systemic exposures to telmisartan >100 times and >25 times, respectively, the systemic exposure in humans receiving the MRHD (80 mg/day).

Genotoxicity assays did not reveal any telmisartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with *Salmonella* and *E. coli* (Ames), a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with human lymphocytes, and a mouse micronucleus test.

No drug-related effects on the reproductive performance of male and female rats were noted at 100 mg/kg/day (the highest dose administered), about 13 times, on a mg/m² basis, the MRHD of telmisartan. This dose in the rat resulted in an average systemic exposure (telmisartan AUC as determined on day 6 of pregnancy) at least 50 times the average systemic exposure in humans at the MRHD (80 mg/day).

**Amlodipine**

Rats and mice treated with amlodipine maleate in the diet for up to two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg amlodipine/kg/day, showed no evidence of a carcinogenic effect of the drug. For the mouse, the highest dose was, on mg/m² basis, similar to the maximum recommended human dose [MRHD] of 10 mg amlodipine/day. For the rat, the highest dose was, on a mg/m² basis, about two and a half times the MRHD. (Calculations based on a 60 kg patient.)

Mutagenicity studies conducted with amlodipine maleate revealed no drug-related effects at either the gene or chromosome level.

There was no effect on the fertility of rats treated orally with amlodipine maleate (males for 64 days and females for 14 days prior to mating) at doses of up to 10 mg amlodipine/kg/day (about 10 times the MRHD of 10 mg/day on a mg/m² basis).
12. ECOLOGICAL INFORMATION

No information available

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

IATA/ICAO - Not Regulated
IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated
IMDG Proper shipping Name : N/A
IMDG UN/ID No : N/A
IMDG Hazard Class : N/A
IMDG Flash Point : N/A
IMDG Label : N/A

DOT - Not Regulated
DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

15. REGULATORY INFORMATION

No information available.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.